SpinTech STAGE and TBI MRI: Regulatory Scope and Limitations

Read the product record precisely

FDA record K210843 identifies STAGE from Spintech, Inc., and a 510(k) substantially equivalent decision dated June 29, 2021. It does not establish blanket FDA approval of all DTI, volumetry, QSM or locally branded TBI protocols.

Ask the center to confirm the installed product, version and intended use. This article does not assert exclusive FDA-cleared technology, a fixed microbleed-detection percentage or a universally faster scan.

What imaging can and cannot establish

A concussion assessment starts with a healthcare provider’s clinical evaluation. Brain imaging is not routinely needed to identify every mild TBI or concussion; the clinician selects tests when they address a specific concern.

CT and MRI can help evaluate some structural injuries, but they cannot detect every TBI. A normal scan does not by itself exclude a concussion, and an abnormality must be interpreted in clinical context.

Advanced methods such as DTI, SWI and quantitative analysis have different uses and limitations. Do not treat a technique, software result or marketing protocol as a stand-alone diagnosis or a guarantee that subtle injury will be found.

Discuss the local examination

Confirm the ordered sequences, scanner compatibility, location and preparation. An educational description of SWI, DTI or QSM does not establish that every center provides those techniques.

Plan for results and follow-up

Ask when the report is expected, how it will reach the ordering clinician and whom to contact if it has not arrived. Routine report timing depends on the study and review process; no fixed delivery deadline is promised here.

The treating clinician interprets the report alongside symptoms, examination findings and prior studies. Imaging does not by itself determine treatment, the cause of an injury or a legal outcome. Request a clinical follow-up plan.